Mass. U.S. Attorney: United States Files Complaint Against Regeneron Pharmaceuticals Alleging Fraudulent Drug Price Reporting
April 11, 2024
April 11, 2024
BOSTON, Massachusetts, April 11 -- The office of the U.S. Attorney for the District of Massachusetts issued the following news release:
The United States has filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals, Inc. (Regeneron), a New York-based pharmaceutical company. The complaint alleges that Regeneron fraudulently manipulated Medicare reimbursement for its drug, Eylea, by knowingly submitting false average sales price (ASP) reports to Medicare. M . . .
The United States has filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals, Inc. (Regeneron), a New York-based pharmaceutical company. The complaint alleges that Regeneron fraudulently manipulated Medicare reimbursement for its drug, Eylea, by knowingly submitting false average sales price (ASP) reports to Medicare. M . . .